CUV Share Price Performance
AU$12.20
-1.79 (-12.79%)
69.4% undervalued intrinsic discount
AU$39.82
Fair Value
Price AU$12.20
AnalystHighTarget AU$39.82
AnalystConsensusTarget AU$24.42
AnalystLowTarget AU$15.00
Fair ValueAU$39.82
Share PriceAU$12.20
69.4% undervalued intrinsic discount
CUV Community Narratives
AN
Fair Value AU$39.82 69.4% undervalued intrinsic discount
Growing Photomedicine Adoption Will Unlock Global Patient Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value AU$24.42 50.0% undervalued intrinsic discount
Advancements In Vitiligo Treatments And Global Expansion Will Drive Future Success
5users have liked this narrative
0users have commented on this narrative
63users have followed this narrative
AN
Fair Value AU$15.00 18.7% undervalued intrinsic discount
Patent Risks And Regulation Will Strain Margins Yet Support Resilience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Recent CUV News & Updates
No updates
Clinuvel Pharmaceuticals Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.78
- Gross Margin
- 90.83%
- Net Profit Margin
- 42.60%
- Debt/Equity Ratio
- 0%
Clinuvel Pharmaceuticals Limited Competitors
About CUV
- Founded
- 1999
- Employees
- n/a
- CEO
- WebsiteView website
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900 and Parvysmelanotide (VLRX001), both alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone to produce cortisol and enables the combat of stress and regulation of immune responses, maintenance of blood pressure, moderation of blood sugar, and regulation of metabolism. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Australian Market Performance
- 7 Days: 1.1%
- 3 Months: 8.3%
- 1 Year: 14.7%
- Year to Date: 7.4%
The market is up 1.1% over the last week, with the Financials sector leading the way, up 1.1%. As for the past 12 months, the market is up 15%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading